je.st
news
Tag: biogen
Biogen buys UK-based neuropathic pain drug developer for up to $675M
2015-01-12 06:43:14| Biotech - Topix.net
Biogen Idec is getting into the neuropathic pain treatment field with the acquisition of a U.K. drug developer for up to $675 million. The Cambridge biotech firm , known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals on the first weekend of the J.P. Morgan Healthcare conference in San Francisco.
Tags: drug
pain
developer
buys
Biogen reports good news with potential neuron-healing drug for MS
2015-01-08 16:16:24| Biotech - Topix.net
The first-ever drug with potential to repair past damage in the brain due to multiple sclerosis scored a win this morning when Biogen Idec reported positive news from a related trial. Based in Cambridge, Massachusetts, Biogen Idec operates a major manufacturing facility in Research Triangle Park.
Tags: news
good
reports
potential
Biogen Rises on Data From Early-Stage Alzheimer's Drug Trial
2014-12-03 00:11:59| Agriculture - Topix.net
Biogen Idec Inc. shares rose after the company said its Alzheimer's drug showed promising early results and will be quickly moved into a final-stage trial. In a small, early stage trial, Biogen's drug BIIB037 reduced beta amyloid in the brain, said Doug Williams, executive vice president of research and development, at a Deutsche Bank conference in Boston today.
Biogen Idec And Swedish Orphan Biovitrum Announce European Medicines...
2014-11-04 04:36:32| Appliances - Topix.net
CAMBRIDGE, Mass. & STOCKHOLM-- --Biogen Idec and Swedish Orphan Biovitrum AB today announced that the European Medicines Agency has validated the Marketing Authorization Application of ELOCTATM , a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA's review process.
Tags: european
swedish
announce
medicines
Biogen Idec and Sobi Announce European Medicines Agency Validates...
2014-10-31 22:14:45| Appliances - Topix.net
CAMBRIDGE, Mass. & STOCKHOLM-- -- Biogen Idec and Swedish Orphan Biovitrum AB today announced that the European Medicines Agency has validated the Marketing Authorization Application of ELOCTAa , a recombinant factor VIII Fc fusion protein product candidate for the treatment of hemophilia A. The validation of the MAA initiates the EMA's review process.
Tags: agency
european
announce
medicines
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »